Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles


Her-Shyong Shiah, M.D.

Assistant Investigator and Attending Physician
National Institute of Cancer Research
hsshiah@nhri.org.tw

EDUCATION

M.D., Medical College of Chung Shan Medical University, Taiwan, 1993

PROFESSIONAL EXPERIENCES


  • Medical Oncologist, Cancer Cooperative Ward at Taipei-VGH, NTUH & NCKUH, Taiwan (2000-present)

  • Hematologist, Division of Hematology, NationalTaiwanUniversityHospital (NTUH), Taiwan (2000-2001)

  • Medical Oncology Fellow, Cancer Cooperative Ward at Taipei-VGH, Taiwan (1998-2000)

  • Internal Medicine Physician, Department of Internal Medicine, Taipei-VGH, Taiwan (1995-1998)

RESEARCH INTERESTS

Before being a standard therapy, a new anti-cancer drug or combinations should be tested in clinical trials, including phase I, II and III trials and pharmacokinetic study. The phase I trial is aimed to find an optimal dose and pharmacokinetic study is to characterize the drug changed in a body. Besides, genetic background will also affect the efficacy of drugs. Currently, Dr. Shiah studies the correlation of polymorphisms in enzymes, cytochrome P450 and UGT, with the metabolism and effect on CPT-11. Dr. Shiah will initiate a phase I trial to realize the optimal dose and interval of CPT-11 in Taiwanese cancer patients, and to surrogate the specific pharmacogenetic factors. The hepatocellular carcinoma is one of the most important causes of cancer death in Taiwan. Dr. Shiah is interested in the feasibility of some drug combinations for this cancer. For example, some signal transduction pathways are aberrant in the
hepatocellular carcinoma. One of those pathways is through PI 3K/Akt/mTOR. Recently, small molecules aimed to block the function of mTOR have been broadly surveyed. He will use an mTOR inhibitor to treat the patients with hepatocellular carcinoma in a phase I/II trial.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Currently, the parmacogenetic study is ongoing. Dr. Shiah and his colleagues have finished one study, which dealed with the pharmacogenetic and pharmacokinetic studies of CPT-11. The result showed that some metabolic enzymes might be important candidates responsible for the efficacy and complication of CPT-11. It will be validated in future studies.

SELECTED PUBLICATIONS


  1. Ch'ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Shiah HS, Liu TW, Chang JY, Whang-Peng J and Chen LT. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-hr infusion of fluorouracil/leucovorin (GOFL) for advanced pancreatic cancer. J Gastroenterol Hepatol, 21(5):874-879, 2006.

  2. Shiah HS, Cheng AL, Hsu C, Hsu CH, Liu TW, Chang JY, Jan CM, Chao Y, Yu WL, Chuang TR, Whang-Peng J and Chen LT. A phase I-II trial of weekly gemcitabine plus 24-h infusion of high dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. J Gastroenterol Hepatol, 21(3):531-536, 2006.

  3. Shiah HS, Liu TW, Chen LT, Chang JY, Liu JM, Chuang TR, Lee WS and Whang-Peng J. Pulmonary embolism after transcatheter arterial chemoembolization. Eur J Cancer Care, 14(5):440-442, 2005.

  4. Liu JM, Chen LT, Li AF, Wu CW, Lan C, Chung TR, Shiah HS, Lee KD, Liu TW and Peng JW. Prognostic Implications of the Expression of erbB2, Topoisomerase II{alpha} and Thymidylate Synthase in Metastatic Gastric Cancer After Fluorouracilbased Therapy. Jpn J Clin Oncol, 34(12):727-732, 2004.

  5. Liu JM, Chen LT, Chao Y, Li AFY, Wu CW, Liu TS, Shiah HS, Chang JY, Chen JD, Wu HW, Lin WC, Lan C and Whang-Peng J. Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. Cancer Chemother Pharmacol, 49(5):425-428, 2002.